Shilpa Medicare Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/nbohhba8iiff2g0nuxjc9g4y.pdf

Key Takeaways


The Inflection Narrative

Bhutada: "I want to start not with the quarter's numbers. We will get to those, and they are the best in our history, but first I want to inform all our investors that the hardest years, the years of investing ahead of revenue, are behind us. The years of harvesting are beginning."

Gross Margin: The Mix Math


Segment Performance

SegmentTrendCommentary
API▲ 24% YoYNon-captive revenue hit ₹255 cr, driven by improved uptake from newly expanded capacities and steady specialty CDMO performance; oncology grew slightly slower than non-oncology.
Formulations▲ >50% YoYRevenue reached ₹210 cr; base business grew 87% ex-licensing, led by complex finished dosage forms in the EU, supported by U.S. and RoW. India grew 2.5x in H1 YoY, led by Nor-UDCA.
Biologics▲ 150% YoYRevenue hit ₹65 cr on continued licensing, partnership and CDMO momentum; only Adalimumab is currently commercially supplied, so the base is still narrow.
CDMO (carve-out)▲ SteadyA dedicated CDMO platform was carved out from the API business; 4 of 25-plus NCE programs are under registration, with at least one expected to commercialize next year and three the subsequent year.

The Pipeline: Loaded, But Mostly FY28+

Bhutada: "Shilpa is not built to compete on price alone. We are built to compete on difficulty and on the complexity of the molecule."

Biologics: From Investment to Business

Bhutada: "Biologics is now a real business focus and no longer an asset under monetization."

Capacity & Competitive Positioning

Dalal: "there is 0 risk to the revenue that we currently have."

Guidance & Commitments

CommitmentSpecificsTimeline
API momentumConfident of continuing API momentumUpcoming quarters
CDMO commercializationAt least 1 of 4 late-stage programs under registration to commercializeNext year; 3 in the subsequent year
Oncology generic completionsMore than 15 new oncology generic productsFY27
Peptide capacityOne of the largest integrated peptide capacities commissionedEnd of FY27
Biosimilars entering human studies2 biosimilars for Europe and RoWFY27
NBE Phase I entryBoth partnership programs (Alveolus Bio, mAb Tree)FY27
CDMO biologics Phase I suppliesSupplies for 3 client programs completedFY27
Recombinant human Albumin IMPDSubmission in EuropeH2 FY27
Nivolumab biosimilar filingFile in EuropeNext year
Enzalutamide, Abraxane, Rotigotine launchThree complex product launchesFY28
Transdermal patch filingFile in EuropeFY28
First ADC biosimilarEnter human studiesFY28
Ondansetron launchLaunch pending state approvalsH1 FY28
505(b)(2) commercialization5-plus complex productsNext 2–3 years
ROCEExpect further improvement with better mix and operating leverageComing quarters

Key Metrics

MetricQ2 FY27
Revenue₹538 cr, highest ever quarterly revenue, +35% YoY
H1 FY27 revenue₹1,007 cr, first time half-yearly revenues crossed ₹1,000 cr mark, +44% YoY
EBITDA₹151 cr, highest ever quarterly EBITDA, +37% YoY
EBITDA margin28%
H1 FY27 EBITDA₹290 cr, +40% YoY, margin of 29%
Operating PBT (before JV/associate profit and exceptionals)₹104 cr
H1 FY27 operating PBT₹202 cr
PAT₹79 cr
H1 FY27 PAT₹180 cr, nearly 100% growth vs H1 FY26
Gross margin decline~700 bps sequentially and YoY (per an analyst's math), driven by higher API sales mix
Raw material cost to sales ratio35.72%, up from 28.65% in Q2 FY26
Non-captive API revenue₹255 cr, +24% YoY
Formulation revenue₹210 cr, +50% YoY
Formulation base business growth (ex-licensing)+87% YoY
Biologics revenue₹65 cr, +150% YoY
Biologics revenue share12% of total revenue
India business H1 growth2.5x YoY
H1 FY27 capex₹252 cr, funded by internal accruals
Net debt₹612 cr, stable despite increased capex
ROCE13.3%, up from 9% in FY25; adjusted ROCE 18.3%
NCE CDMO client programs25-plus, of which 4 partners' programs expected to commercialize in next 18–24 months
CDMO late-stage programs4 under registration, 2 in Phase III; at least 1 expected to commercialize next year, 3 in subsequent year
Biologics CDMO active programs6-plus; Phase I supplies for 3 programs to be completed in FY27
Biosimilars portfolio7 molecules, average global sales of more than USD 1,000 cr each
Peptide manufacturing lines4 currently, adding 2 more; one of the largest integrated peptide capacities in India to commission by end of FY27
Peptide investment announcedUSD 50 million, phased